XORTX Therapeutics (TSXV:XRTX) Long-Term Capital Lease Obligation : C$0.00 Mil (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is XORTX Therapeutics Long-Term Capital Lease Obligation?

XORTX Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Sep. 2024 was C$0.00 Mil.

XORTX Therapeutics's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (C$0.00 Mil) to Dec. 2022 (C$0.02 Mil) but then declined from Dec. 2022 (C$0.02 Mil) to Dec. 2023 (C$0.00 Mil).

XORTX Therapeutics Long-Term Capital Lease Obligation Historical Data

The historical data trend for XORTX Therapeutics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics Long-Term Capital Lease Obligation Chart

XORTX Therapeutics Annual Data

Trend

Feb15

Feb16

Feb17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.02

XORTX Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	-	-	-	-

XORTX Therapeutics (TSXV:XRTX) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

XORTX Therapeutics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

XORTX Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (TSXV:XRTX) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

XRTX:USA ANUA:Germany

Address

3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1

Website

https://www.xortx.com

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

Executives

Allen Warren Davidoff	Director, Senior Officer
Amar Deep Keshri	Senior Officer
William Bruce Rowlands	Director
James Neville Fairbairn	Senior Officer
Allan William Williams	Director
Paul Joseph Van Damme	Director